DARA-IM: An Integrated In Silico Phase Ib/II Clinical Trial of Daraxonrasib Plus Ivermectin and Mebendazole Versus Daraxonrasib Monotherapy in Previously Treated Stage IV Pancreatic Cancer

Article type: Proposed research protocol and computational modelling framework

Research group: OneDayMD / SmartCancer Research Team

Protocol version: 1.2

Protocol date: 17 November 2026

Study designation: DARA-IM (Daraxonrasib–Ivermectin–Mebendazole)

Clinical setting: Second-line treatment of metastatic pancreatic ductal adenocarcinoma (PDAC)

Research design: Integrated Phase Ib/II virtual clinical trial

Research disclaimer: DARA-IM is a proposed computational and translational research protocol. The three-drug combination has not demonstrated clinical efficacy or established safety in pancreatic cancer. This article does not recommend ivermectin or mebendazole as cancer treatments, and no experimental dosing regimen is proposed for patient use. Any human investigation would require pharmacological validation, regulatory authorization and independent ethics approval.

Abstract

Background

Metastatic pancreatic ductal adenocarcinoma (PDAC) remains a major therapeutic challenge. Daraxonrasib, a RAS(ON) multi-selective inhibitor, has emerged as an important treatment option for previously treated metastatic pancreatic adenocarcinoma. Ivermectin and mebendazole have demonstrated experimental anticancer activity in selected preclinical models, but their clinical efficacy in PDAC remains unestablished.

Objective

To develop an integrated in silico Phase Ib/II research framework investigating whether the addition of ivermectin and mebendazole to daraxonrasib could provide incremental antitumour activity compared with daraxonrasib monotherapy in previously treated Stage IV PDAC.

Methods

A two-arm virtual clinical trial is proposed. Arm A receives daraxonrasib monotherapy. Arm B receives daraxonrasib combined with ivermectin and mebendazole, subject to pharmacokinetic and safety feasibility. The virtual population comprises adults with metastatic PDAC following one previous systemic chemotherapy line, irrespective of RAS/KRAS mutation status. Molecular stratification will include KRAS G12D, G12V, G12R, G12C, other RAS alterations and patients without a detectable RAS alteration. The computational framework integrates population pharmacokinetics, pharmacodynamics, tumour growth, drug synergy, resistance modelling, toxicity prediction and survival analysis.

Primary endpoint

Progression-free survival (PFS).

Secondary endpoints

Overall survival, objective response rate, duration of response, disease control rate, CA19-9 response, circulating tumour DNA response, quality of life and treatment-related toxicity.

Conclusion

DARA-IM provides a structured framework for investigating the biological plausibility, pharmacological feasibility and potential safety of combining daraxonrasib with two repurposed drugs. The combination should advance to clinical investigation only if clinically achievable exposures, reproducible additional antitumour activity and an acceptable safety profile can be established.

Keywords: pancreatic cancer; PDAC; metastatic pancreatic adenocarcinoma; daraxonrasib; RMC-6236; ivermectin; mebendazole; drug repurposing; RAS inhibition; in silico clinical trial; pharmacokinetics; precision oncology.


1. Introduction

1.1 The therapeutic challenge in metastatic pancreatic cancer

Pancreatic ductal adenocarcinoma is characterized by aggressive tumour biology, early metastatic dissemination, extensive molecular heterogeneity and a complex tumour microenvironment.

Although combination chemotherapy has improved outcomes, metastatic PDAC remains difficult to control. Resistance, disease progression, treatment toxicity and declining performance status frequently limit therapeutic options.

RAS signalling is particularly important in PDAC. KRAS mutations occur in the majority of pancreatic ductal adenocarcinomas and contribute to tumour proliferation, survival and resistance-associated signalling.

Pancreatic Cancer Breakthrough 2026

1.2 Daraxonrasib as the treatment backbone

Daraxonrasib (RASONQUE; formerly RMC-6236) is an oral RAS(ON) multi-selective inhibitor. It forms a tri-complex involving cyclophilin A and active GTP-bound RAS, disrupting interactions between RAS and downstream signalling effectors.

On 26 August 2026, the US Food and Drug Administration approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multi-agent systemic therapy.

In the randomized Phase 3 RASolute 302 study (NCT06625320), involving 500 previously treated patients, the overall-population results were:

Outcome Daraxonrasib Chemotherapy
Median overall survival13.2 months6.7 months
Median progression-free survival7.2 months3.6 months
Objective response rate30%11%
OS hazard ratio0.40
PFS hazard ratio0.49

These are observed results from RASolute 302, not predicted outcomes for DARA-IM. They provide the clinical benchmark for the proposed daraxonrasib monotherapy control arm.

Reference: FDA approval of daraxonrasib, 26 August 2026.

1.3 Rationale for investigating ivermectin

Ivermectin is an antiparasitic agent that has attracted experimental oncology interest because of reported effects on multiple cellular pathways, mitochondrial function, apoptosis and cellular transport mechanisms.

A 2022 pancreatic cancer study investigated ivermectin in patient-derived organoids and experimental pancreatic cancer models. Ivermectin inhibited organoid proliferation at experimental concentrations of 6 and 8 μM. The study also investigated combination treatment with gemcitabine and reported mitochondrial dysfunction and increased apoptosis.

These findings provide a preclinical rationale for additional investigation. They do not establish that ivermectin improves clinical outcomes in pancreatic cancer or that its effects are complementary to daraxonrasib.

Reference: Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via mitochondrial dysfunction. Frontiers in Pharmacology. 2022.

1.4 Rationale for investigating mebendazole

Mebendazole is a benzimidazole antiparasitic drug with experimental microtubule-disrupting and antiproliferative properties.

Preclinical pancreatic cancer research has investigated mebendazole in genetically engineered KC and KPC mouse models. Reported findings included effects on tumour development, tumour burden, stromal desmoplasia and metastatic involvement.

The KPC model, which incorporates oncogenic KRAS and TP53 alterations, is particularly relevant to the molecular biology of PDAC. Nevertheless, animal-model results cannot be directly translated into human survival estimates.

1.5 Combination hypothesis

The proposed combination investigates three potentially complementary mechanisms:

AgentExperimental roleResearch question
DaraxonrasibRAS pathway inhibitionDoes RAS suppression reduce tumour growth?
IvermectinExperimental signalling and mitochondrial effectsDoes it provide additional tumour-cell inhibition?
MebendazoleMicrotubule disruptionDoes it provide additional antiproliferative activity?

The central hypothesis is that the additional agents may provide incremental anticancer activity or affect resistance mechanisms. Additive or synergistic effects must be demonstrated experimentally rather than assumed.


2. Study objectives

2.1 Primary objective

To determine whether adding ivermectin and mebendazole to daraxonrasib improves progression-free survival compared with daraxonrasib monotherapy.

2.2 Secondary objectives

  • Evaluate overall survival.
  • Compare objective response rate.
  • Assess duration of response and disease control rate.
  • Evaluate CA19-9 and circulating tumour DNA responses.
  • Assess quality of life.
  • Estimate grade 3–4 adverse events.
  • Evaluate hepatotoxicity and neurological toxicity.
  • Assess treatment interruptions and discontinuation.
  • Characterize pharmacokinetic interactions between the three agents.

2.3 Exploratory objectives

  • Investigate differences according to KRAS and other RAS mutation status.
  • Identify potential biomarkers of response and resistance.
  • Assess changes in RAS/MAPK signalling.
  • Evaluate apoptosis and cell-cycle markers.
  • Investigate tumour microenvironment and stromal characteristics.
  • Examine whether previous chemotherapy influences subsequent treatment response.

3. Materials and Methods

3.1 Study design

DARA-IM is proposed as an integrated Phase Ib/II translational research programme consisting of:

  1. Phase Ib: Pharmacokinetic interaction, exposure feasibility, safety and tolerability investigation.
  2. Phase II: Randomized two-arm efficacy simulation comparing daraxonrasib monotherapy with the experimental three-drug combination.

The computational component will use synthetic patient profiles calibrated against published clinical evidence. Synthetic patients must be clearly distinguished from actual clinical participants.

3.2 PICO framework

PopulationAdults with Stage IV metastatic PDAC after one previous systemic treatment line.
InterventionDaraxonrasib + ivermectin + mebendazole.
ComparatorDaraxonrasib monotherapy.
Primary outcomeProgression-free survival.
Secondary outcomesOverall survival, ORR, duration of response, toxicity and quality of life.

3.3 Patient eligibility

Inclusion criteria
  • Age 18 years or older.
  • Histologically or cytologically confirmed pancreatic ductal adenocarcinoma.
  • Stage IV metastatic disease.
  • Documented progression after one previous systemic treatment line for metastatic disease.
  • Previous fluoropyrimidine-based or gemcitabine-based treatment.
  • ECOG performance status 0–1 for the primary model.
  • Measurable disease according to RECIST 1.1.
  • Adequate baseline organ function.
  • Available tumour molecular profiling or validated circulating tumour DNA testing.
Exclusion criteria
  • Pancreatic neuroendocrine tumours and non-PDAC histologies.
  • Previous daraxonrasib or relevant RAS(ON) inhibitor treatment.
  • Uncontrolled hepatic dysfunction.
  • Severe neurological conditions that complicate toxicity assessment.
  • Unmanageable concomitant drug interactions.
  • Pregnancy or breastfeeding.

Patients with actionable alterations requiring established biomarker-directed treatment should be assessed separately. The proposed research must not displace an indicated standard treatment.

3.4 Previous chemotherapy stratification

Previous treatmentStratum
FOLFIRINOX / modified FOLFIRINOXFluoropyrimidine-based
NALIRIFOXFluoropyrimidine-based
Gemcitabine + nab-paclitaxelGemcitabine-based
Other appropriate regimensOther / exploratory

3.5 Molecular stratification

The study includes all eligible Stage IV PDAC patients, irrespective of RAS mutation status. Molecular profiling will classify patients into:

  • KRAS G12D.
  • KRAS G12V.
  • KRAS G12R.
  • KRAS G12C.
  • Other KRAS alterations.
  • NRAS and HRAS alterations.
  • No RAS alteration detected.
  • Unknown or indeterminate molecular status.

Co-mutations including TP53, SMAD4, CDKN2A, BRCA1/2 and PALB2 will also be recorded.

RAS status, previous chemotherapy backbone and ECOG performance status should be considered for randomization stratification. Liver metastases should also be considered, subject to sample-size feasibility.

The primary efficacy analysis will include the entire eligible population. Molecular subgroup analyses will be exploratory unless independently powered.

3.6 Experimental treatment arms

Arm A — Active control

Daraxonrasib monotherapy.

Reference US prescribing-information regimen: 300 mg orally once daily until progression or unacceptable toxicity, subject to approved dose modifications.

Arm B — Experimental combination

Daraxonrasib + ivermectin + mebendazole.

Daraxonrasib provides the treatment backbone. Ivermectin and mebendazole are investigational additions. Their combination exposures must be established through pharmacokinetic and safety investigation before any efficacy expansion.

No ivermectin or mebendazole oncology dose is assumed in this protocol. Experimental anticancer concentrations must not be equated with safe human dosing.


4. Pharmacokinetic and Safety Assessment

4.1 Ivermectin exposure feasibility

Pancreatic cancer organoid experiments have reported ivermectin activity at 6–8 μM. The relevance of these concentrations to safe human plasma and tumour exposure is uncertain.

The model should evaluate Cmax, AUC, free-drug concentration, tumour penetration, CYP3A4 metabolism and P-glycoprotein transport.

4.2 Mebendazole exposure feasibility

A Phase 2a study in advanced gastrointestinal cancers attempted to achieve a serum mebendazole concentration of 300 ng/mL (approximately 1 μM). Despite individualized dosing, consistent achievement of the target concentration was difficult. All eight participants who underwent the eight-week tumour assessment had progressive disease.

These findings raise important questions about absorption, systemic availability and tumour penetration.

4.3 Drug interactions

Daraxonrasib is a CYP3A substrate and P-glycoprotein inhibitor. Ivermectin is affected by CYP3A4 metabolism and P-glycoprotein transport. The magnitude and clinical significance of any interaction in the proposed combination remain unknown.

Potential interactions must be investigated using validated pharmacokinetic models and appropriate laboratory and clinical studies. Dose separation alone must not be assumed to eliminate an interaction.

4.4 Safety monitoring

DomainMonitoring
HepaticALT, AST, ALP, bilirubin
RenalCreatinine, eGFR
NeurologicalNeurological examination and symptom assessment
HaematologicalFull blood count
GastrointestinalNausea, vomiting, diarrhoea and abdominal symptoms
DermatologicalRash, pruritus and skin toxicity
CardiopulmonarySymptoms of pneumonitis or other serious toxicity

5. Phase Ib: Pharmacokinetic and Safety Investigation

5.1 Objectives

  1. Characterize pharmacokinetics of the combination.
  2. Identify clinically relevant drug interactions.
  3. Assess whether experimental anticancer exposures are achievable.
  4. Evaluate dose-limiting toxicities.
  5. Determine whether an acceptable combination exposure exists.

5.2 Proposed structure

ParameterProposed design
PopulationPreviously treated metastatic PDAC
BackboneDaraxonrasib
Experimental agentsIvermectin and mebendazole
Initial safety window28 days, as a modelling assumption
Primary outcomeDose-limiting toxicity and PK feasibility
Secondary outcomePharmacodynamic and preliminary tumour response

A model-assisted Bayesian dose-escalation strategy may be evaluated. Sentinel exposure, staggered introduction where justified, predefined stopping rules and independent safety oversight are required for any actual human investigation.

The combination must not proceed to Phase II if safe and pharmacologically meaningful exposure cannot be demonstrated.

6. Phase II: Randomized Efficacy Investigation

6.1 Design

  • Randomized, two-arm study.
  • Open-label treatment assignment.
  • 1:1 allocation.
  • Blinded independent central radiology review.
  • Intention-to-treat primary analysis.
  • Molecularly stratified randomization.

6.2 Endpoints

Primary endpoint

Progression-free survival measured from randomization until radiological or clinical progression or death, according to the prespecified definition.

Secondary endpoints
  • Overall survival.
  • Objective response rate according to RECIST 1.1.
  • Duration of response.
  • Disease control rate.
  • CA19-9 response.
  • Circulating tumour DNA response.
  • Quality of life.
  • Grade 3–4 adverse events.

6.3 Assessment schedule

AssessmentBaselineEvery 4 weeksEvery 8 weeks
Clinical examinationYesYes
ECOGYesYes
Blood count and chemistryYesYes
CA19-9YesYes
ctDNAYesSelected time points
PharmacokineticsYesAccording to PK plan
CT/MRIYesYes
Quality of lifeYesYes

7. Computational Methodology

7.1 Virtual patient generation

The model will initially generate 10,000 synthetic patient profiles per treatment arm for Monte Carlo uncertainty analysis. This number is a computational choice and does not represent actual clinical enrolment.

Each profile should contain:

  • Demographics and body weight.
  • ECOG performance status.
  • Metastatic sites and tumour burden.
  • KRAS, NRAS and HRAS mutation status.
  • TP53, SMAD4 and CDKN2A alterations.
  • Previous chemotherapy regimen and treatment response.
  • Albumin, bilirubin, liver enzymes and renal function.
  • Baseline CA19-9 and ctDNA.
  • Relevant concomitant medications and pharmacokinetic factors.

7.2 Module 1: Tumour biology

The tumour model should include RAS signalling, MAPK activity, proliferation, apoptosis, tumour heterogeneity, stromal interactions and acquired resistance.

A simplified logistic tumour-growth equation is:

dT/dt = rT(1 − T/K) − E(t)T

Where T represents tumour burden, r represents intrinsic growth rate, K represents carrying capacity and E(t) represents treatment-associated tumour inhibition.

Treatment effects must be calibrated using experimental pharmacodynamic data rather than assumed clinical survival improvements.

7.3 Module 2: Pharmacokinetics

A simplified one-compartment oral model may be used initially:

dC/dt = (F × Dose/V) × Input(t) − (CL/V)C

Where F is bioavailability, V is apparent volume of distribution, CL is clearance and C is drug concentration.

The full model should incorporate absorption, protein binding, active metabolites, multiple compartments where supported and drug interactions.

Outputs include Cmax, Tmax, AUC, half-life, free drug concentration, interpatient variability and estimated tumour exposure.

7.4 Module 3: Drug synergy

Experimental concentration-response data should be used to evaluate combinations through:

  • Bliss independence.
  • Loewe additivity.
  • Highest single agent analysis.
  • Combination index.

Results from cell lines and organoids should be interpreted as preclinical evidence, not proof of clinical synergy.

7.5 Module 4: Toxicity

Adverse-event probabilities should be modelled according to drug exposure, baseline patient characteristics, organ function and concomitant medications.

The model should estimate the probability of Grade 3 or higher toxicity, hepatotoxicity, neurological events, gastrointestinal toxicity, treatment interruption and treatment discontinuation.

7.6 Module 5: Clinical outcomes

The final module should translate tumour response, resistance and toxicity into PFS, OS, ORR, duration of response and quality-adjusted survival.

8. Statistical Analysis Plan

8.1 Progression-free survival

The primary treatment comparison is expressed as:

HR(PFS) = hB(t) / hA(t)

Where hB(t) represents the progression hazard in Arm B and hA(t) represents the progression hazard in Arm A. An HR below 1 favours the experimental combination.

8.2 Overall survival

Overall survival is measured from randomization until death from any cause. Subsequent treatments, treatment discontinuation and crossover should be considered in the modelling framework.

8.3 Response rate

ORR = (CR + PR) / N evaluable × 100

DCR = (CR + PR + SD) / N evaluable × 100

CR represents complete response, PR partial response and SD stable disease.

8.4 Bayesian modelling

A Bayesian framework is appropriate because there are no established human efficacy estimates for ivermectin and mebendazole combined with daraxonrasib.

The prior for incremental combination efficacy should be conservative and centred on no additional benefit:

log(HR) ~ Normal(0, σ²)

Preclinical evidence may inform mechanistic assumptions and prior uncertainty, but must not be converted directly into favourable human hazard ratios. Case reports should not establish efficacy priors.

8.5 Sensitivity analysis

  1. No incremental effect from either repurposed drug.
  2. Incremental ivermectin effect only.
  3. Incremental mebendazole effect only.
  4. Additive combination effects.
  5. Synergistic combination effects.
  6. Increased toxicity or unfavourable drug interaction.
  7. RAS-mutated versus RAS-wild-type disease.
  8. Previous FOLFIRINOX versus gemcitabine-based chemotherapy.
  9. Liver-dominant versus non-liver-dominant disease.
  10. Different baseline performance and tumour burden categories.

8.6 Sample-size scenarios

Computational scenarios may examine 100, 150, 200 and 300 actual hypothetical clinical participants, with equal allocation between the two arms.

These are candidate simulation scenarios, not a final clinical sample-size recommendation. Final power calculations must incorporate the expected control-arm PFS, minimum clinically meaningful hazard ratio, type I error, power, accrual duration, follow-up, dropout and event requirements.

9. Model Calibration and Validation

The daraxonrasib control arm must reproduce established RASolute 302 outcomes before the experimental combination is evaluated.

Calibration targetPublished reference
Median OS, daraxonrasib13.2 months
Median PFS, daraxonrasib7.2 months
ORR, daraxonrasib30%
Median OS, chemotherapy6.7 months
Median PFS, chemotherapy3.6 months
ORR, chemotherapy11%

These are calibration targets, not guaranteed simulation outputs.

Validation should include survival distribution reproduction, response-rate calibration, molecular subgroup assessment, alternative survival distributions, missing-data sensitivity and external validation.

10. Anticipated Results and Decision Framework

No experimental survival advantage should be reported before the computational model has been implemented and validated.

FindingInterpretationDecision
No additional tumour inhibitionNo incremental activityStop efficacy development
Activity only at unattainable exposurePharmacological infeasibilityStop or redesign
Unacceptable toxicityUnfavourable therapeutic windowDo not advance
Modest activity with acceptable exposurePreliminary signalFurther translational work
Reproducible synergy with acceptable exposureStronger biological rationaleConsider clinical development

11. Resistance Mechanisms and Translational Biomarkers

The study should investigate whether additional treatment effects could influence resistance to RAS inhibition.

Potential resistance mechanisms include MAPK reactivation, receptor tyrosine kinase feedback, alternative survival pathways, tumour heterogeneity and stromal-mediated resistance.

Exploratory biomarkers may include phosphorylated ERK, RAS pathway activity, apoptosis markers, cell-cycle activity, microtubule integrity and circulating tumour DNA.

Patient-derived organoids and serial molecular profiling could help determine whether the experimental agents provide reproducible additional pharmacodynamic activity.

12. Ethical and Regulatory Considerations

This is a proposed research protocol, not a treatment recommendation.

The combination is investigational and its safety with daraxonrasib has not been established. Any actual human investigation requires regulatory authorization, institutional research ethics approval, informed consent, clinical trial registration and independent safety monitoring.

The FDA approval of daraxonrasib applies to its defined US indication. Regulatory approval and access may differ in Malaysia and other jurisdictions.

13. Limitations

  • Preclinical translation: Cell-line, organoid and animal findings do not necessarily predict human clinical efficacy.
  • Exposure feasibility: Ivermectin and mebendazole may not achieve experimental anticancer concentrations safely in human tumours.
  • Drug interactions: The combined pharmacokinetics of all three drugs remain insufficiently characterized.
  • Molecular heterogeneity: PDAC includes different molecular and biological subgroups.
  • Case-report bias: Patient reports are vulnerable to selection bias, confounding and incomplete documentation.
  • Synthetic data limitations: A large simulated population cannot compensate for inadequate source data or incorrect model assumptions.
  • External validity: Clinical trial populations may not fully represent routine oncology patients.

14. Conclusion

DARA-IM proposes a two-arm, second-line virtual clinical trial investigating whether ivermectin and mebendazole can provide additional anticancer activity when combined with daraxonrasib in metastatic pancreatic ductal adenocarcinoma.

Daraxonrasib provides a clinically validated treatment backbone. Ivermectin and mebendazole offer experimental mechanisms that justify further investigation but have not demonstrated clinical efficacy in this combination or established efficacy against metastatic PDAC.

The principal challenge is to establish whether the additional agents can achieve adequate tumour exposure at tolerable concentrations without compromising daraxonrasib exposure or increasing toxicity.

The integrated Phase Ib/II approach offers a structured framework for examining these questions.

Key conclusion: The primary objective is not to generate an optimistic simulated survival advantage. It is to establish whether the three-drug combination is pharmacologically feasible, biologically credible and sufficiently safe to justify further human investigation.

15. References

  1. US Food and Drug Administration. FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma. 26 August 2026. FDA.
  2. US Food and Drug Administration. RASONQUE (daraxonrasib) Prescribing Information. Revised August 2026. Prescribing information.
  3. US Food and Drug Administration. NDA 220910: Multidisciplinary Review and Evaluation. Regulatory review.
  4. Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via mitochondrial dysfunction. Frontiers in Pharmacology. 2022. doi:10.3389/fphar.2022.934746.
  5. A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer. Scientific Reports. 2021;11:8981. doi:10.1038/s41598-021-88433-y.
  6. Mebendazole pancreatic cancer preclinical research. PubMed literature search.
  7. RASolute 302, NCT06625320. ClinicalTrials.gov.
  8. RASolute 303, NCT07491445. ClinicalTrials.gov.
  9. OneDayMD. Stage 4 pancreatic cancer and fenbendazole: research and reported cases. OneDayMD.
  10. SmartCancer. Pancreatic cancer treatment: research and treatment strategies. SmartCancer.

Suggested citation: OneDayMD Research Team. DARA-IM: An Integrated In Silico Phase Ib/II Clinical Trial of Daraxonrasib Plus Ivermectin and Mebendazole Versus Daraxonrasib Monotherapy in Previously Treated Stage IV Pancreatic Cancer. Proposed research protocol. Version 1.0. 2026.

Research classification: Hypothesis-generating translational oncology protocol. No clinical trial results are reported.

Comments

Popular posts from this blog

Top 20 Cancer Fighting Supplements: Evidence Based Literature Review (2026 Update)

Ivermectin for Cancer: Dr. William Makis Protocol and Others Explained (2026 Guide)

Dr. William Makis's Recommended Ivermectin, Fenbendazole and Mebendazole Dosages for Cancer (2026)

Ivermectin, Fenbendazole & Mebendazole for Cancer: 2026 Evidence Guide

Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2026)

Fenbendazole and the Joe Tippens Protocol (2026): Evidence, Risks, and Current Perspective

Ivermectin & Fenbendazole for Lung Cancer: 63 Cases Analyzed (2026)

Ivermectin Dosage for Cancer in 2026: Marik vs Makis vs Hope — What the Numbers Actually Are

Cancer Prevention Supplements & Diet: The I-PREVENT + ROOT Protocol (2026)

Fact Check: Can Ivermectin and Fenbendazole Help Treat Cancer?

Archive

Show more